Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis

Stanley Krolczyk; Kelly L. Sullivan

Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis

Biostatistics, Epidemiology, & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2009

DC Disciplines

Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{fa606a5aae1c456999e6e49577a4a2aa,

title = "Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis",

author = "Stanley Krolczyk and Sullivan, {Kelly L.}",

note = "Stanley Krolczyk (Principal Investigator) and Kelly L. Sullivan (Collaborator), {"}Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis,{"} Genzyme Corporation. (2009-2012).",

year = "2009",

language = "American English",

type = "Other",

}

TY - GEN

T1 - Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis

AU - Krolczyk, Stanley

AU - Sullivan, Kelly L.

N1 - Stanley Krolczyk (Principal Investigator) and Kelly L. Sullivan (Collaborator), "Characterization of Immunological Reconstitution Following Alemtuzumab Therapy in Patients with Relapsing Remitting Multiple Sclerosis," Genzyme Corporation. (2009-2012).

PY - 2009

Y1 - 2009

M3 - Other

ER -